Mercer Global Advisors
MRNA icon

Mercer Global Advisors’s Moderna MRNA Stock Holding History

Mercer Global Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Buy
46,403
+5,497
+13% +$284K ﹤0.01% 1084
2026
Q1 		$2.08M Sell
40,906
-67,744
-62% -$3.16M ﹤0.01% 1185
2025
Q4 		$3.2M Buy
108,650
+99,678
+1,111% +$2.71M ﹤0.01% 903
2025
Q3 		$232K Buy
8,972
+1,399
+18% +$39K ﹤0.01% 2278
2025
Q2 		$209K Sell
7,573
-192
-2% -$5.06K ﹤0.01% 2064
2025
Q1 		$220K Buy
7,765
+371
+5% +$13.2K ﹤0.01% 1909
2024
Q4 		$307K Sell
7,394
-7,242
-49% -$346K ﹤0.01% 1726
2024
Q3 		$937K Sell
14,636
-8,442
-37% -$775K ﹤0.01% 1043
2024
Q2 		$2.72M Sell
23,078
-2,015
-8% -$255K 0.01% 625
2024
Q1 		$2.67M Sell
25,093
-11,221
-31% -$1.13M 0.01% 642
2023
Q4 		$3.61M Sell
36,314
-1,495
-4% -$126K 0.01% 556
2023
Q3 		$3.9M Sell
37,809
-31,053
-45% -$3.46M 0.01% 505
2023
Q2 		$8.37M Buy
68,862
+1,262
+2% +$168K 0.03% 331
2023
Q1 		$10.4M Buy
67,600
+2,945
+5% +$486K 0.05% 263
2022
Q4 		$11.6M Buy
64,655
+11,773
+22% +$1.92M 0.06% 244
2022
Q3 		$6.25M Buy
52,882
+20,278
+62% +$3.08M 0.04% 323
2022
Q2 		$4.66M Buy
32,604
+3,618
+12% +$517K 0.03% 389
2022
Q1 		$4.99M Buy
28,986
+11,905
+70% +$2M 0.03% 382
2021
Q4 		$4.34M Buy
17,081
+1,204
+8% +$352K 0.03% 410
2021
Q3 		$6.11M Buy
15,877
+9,337
+143% +$3.44M 0.04% 303
2021
Q2 		$1.54M Buy
6,540
+1,257
+24% +$225K 0.01% 670
2021
Q1 		$692K Sell
5,283
-359
-6% -$52K 0.01% 936
2020
Q4 		$589K Sell
5,642
-1,348
-19% -$136K 0.01% 800
2020
Q3 		$495K Buy
6,990
+2,643
+61% +$184K 0.01% 783
2020
Q2 		$279K Buy
+4,347
New +$238K 0.01% 874

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Mercer Global Advisors's MRNA Position: Q2 2026 in Review

Mercer Global Advisors increased its Moderna (MRNA) stake by 13% in Q2 2026, buying an estimated $284K and bringing the position to 46,403 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1084.

Mercer Global Advisors first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $11.6M in Q4 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Mercer Global Advisors held 46,403 shares of Moderna worth $3.25M as of Q2 2026.
  • Mercer Global Advisors bought 5,497 Moderna shares in Q2 2026, an estimated $284K.
  • Moderna made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #1084 holding.
  • Mercer Global Advisors first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Mercer Global Advisors's Moderna position peaked at $11.6M in Q4 2022.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.